STOCK TITAN
  1. Home
  2. News
  3. COCP

Cocrystal Pharma, Inc. - COCP STOCK NEWS

Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.

Cocrystal Pharma, Inc. (symbol: COCP) is an innovative pharmaceutical company dedicated to discovering and developing novel antiviral therapeutics. With a primary focus on treating serious and chronic viral diseases, Cocrystal employs advanced technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. By leveraging unique nucleoside chemistry and a market-focused approach to drug discovery, the company aims to deliver small molecule therapeutics that are safe, effective, and convenient to administer.

The company has made significant strides in identifying promising preclinical stage antiviral compounds that address unmet medical needs. These include treatments for hepatitis, influenza, and norovirus infections. Among its notable projects, Cocrystal Pharma is developing CC-31244, an oral, broad-spectrum replication inhibitor known as a non-nucleoside inhibitor (NNI). This investigational drug targets the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses, showcasing the company's commitment to creating groundbreaking antiviral solutions.

Cocrystal Pharma has garnered strategic investments from major industry players such as Teva Pharmaceuticals, Opko Health (OPK), Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group. This backing underscores the confidence that leading pharmaceutical entities have in Cocrystal's potential and technological capabilities.

As Cocrystal Pharma continues to advance its pipeline of antiviral therapeutics, the company's innovative approach and robust partnerships position it as a significant player in the biotechnology sector. Investors and stakeholders can stay updated on the latest developments, financial reports, and strategic initiatives that propel Cocrystal Pharma forward in its mission to combat viral diseases.

For those interested in the latest updates and relevant information regarding Cocrystal Pharma and its stock performance, be sure to check the latest news and announcements below.

  • ---
  • ---
  • ---
  • ---
  • ---
  • ---
News

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Rhea-AI Summary
Cocrystal Pharma, Inc. (COCP) receives positive FDA feedback on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344. The company plans to file an IND for late-stage clinical development in 2024, with topline data expected from Phase 2a influenza A human challenge study. Additionally, a Phase 1 study with oral CDI-988 and Phase 1 study with inhaled CC-42344 are set to commence in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
earnings
-
News

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Rhea-AI Summary
Cocrystal Pharma, Inc. receives positive Pre-IND feedback from the FDA for CC-42344 oral treatment for influenza A, setting the stage for Phase 2b trial. The company is progressing well with ongoing Phase 2a study in the UK and preparing for Phase 1 study in Australia. CC-42344 shows promising antiviral activity against various influenza strains and exhibits favorable safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
none
-
News

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Rhea-AI Summary
Planet MicroCap releases a Video Interview with Cocrystal Pharma's Co-CEO and CFO, Jim Martin, discussing the company's novel antiviral therapeutics targeting various viruses. The interview highlights Cocrystal Pharma's clinical development and 2024 value catalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
management clinical trial
News

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

Rhea-AI Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A. The preliminary data of the ongoing Phase 2a and Phase 1 studies showed CC-42344 and CD-988 were well-tolerated with favorable safety profiles. CDI-988 targets a highly conserved region in the active site of the main 3CL protease required for viral RNA replication for pandemic norovirus and coronaviruses, including SARS-CoV-2. CC-42344 binds to a highly conserved PB2 site of the influenza A polymerase complex and exhibits a novel mechanism of action that inhibits viral replication. Cocrystal expects to report topline results from the Phase 1 and Phase 2a studies this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Rhea-AI Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A. The trial will evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment. The company expects to report topline data from this clinical trial in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Rhea-AI Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces positive data on its PB2 inhibitor CC-42344 for influenza treatment and prophylaxis. The company has initiated Phase 2a human challenge trial with oral CC-42344 in the UK and plans to begin a Phase 1 trial with inhaled CC-42344 in Australia in 2024. President and co-CEO Dr. Sam Lee discussed the superior antiviral activity of CC-42344 compared to Tamiflu, its novel mechanism of action, and successful delivery into the lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
News

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Rhea-AI Summary
Cocrystal Pharma, Inc. (COCP) announces CFO and Co-CEO James Martin to present at Noble Capital Markets' conference, discussing upcoming antiviral development program data and near-term milestones. The webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.12%
Tags
conferences
-
News

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Rhea-AI Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP): Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviral. Dosing expected to begin later this year in Phase 2a human challenge trial with oral CC-42344 for the treatment of pandemic and seasonal influenza A. Phase 1 trial with inhaled CC-42344 expected to begin in the first half of 2024. The company reports financial results for the three and nine months ended September 30, 2023, and provides updates on its antiviral pipeline, upcoming milestones, and business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
earnings
-
News

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Rhea-AI Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces President and co-CEO Sam Lee, PhD will discuss progress in developing the novel, broad-spectrum PB2 inhibitor CC-42344 in an oral presentation at the World Vaccine Congress West Coast. Dr. Lee will talk about the significant progress made in developing CC-42344 for the treatment of pandemic and seasonal influenza A. Cocrystal recently announced authorization by the United Kingdom MHRA to initiate a Phase 2a human challenge trial with orally administered CC-42344 and expects to begin treating influenza-infected patients later this quarter. Preparations are also underway to begin a Phase 1 clinical trial in the first half of 2024 with an inhaled CC-42344 formulation as a potential treatment and prophylaxis for influenza A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
none
News

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Rhea-AI Summary
Cocrystal Pharma, Inc. has received authorization from the UK Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human challenge trial for its PB2 inhibitor CC-42344 as a potential treatment for influenza A. The trial is expected to begin in Q4 2023 and aims to evaluate the safety and effectiveness of CC-42344 in influenza-infected subjects. Cocrystal's Phase 1 trial showed positive safety and tolerability results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
clinical trial

FAQ

What is the current stock price of Cocrystal Pharma (COCP)?

The current stock price of Cocrystal Pharma (COCP) is $2.06 as of November 20, 2024.

What is the market cap of Cocrystal Pharma (COCP)?

The market cap of Cocrystal Pharma (COCP) is approximately 21.4M.

What does Cocrystal Pharma, Inc. do?

Cocrystal Pharma, Inc. is a pharmaceutical company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases.

What are Cocrystal Pharma's key areas of focus?

The company focuses on creating antiviral treatments for hepatitis, influenza, and norovirus infections.

What is CC-31244?

CC-31244 is an investigational, oral, broad-spectrum replication inhibitor developed by Cocrystal Pharma to target the replication machinery of influenza, hepatitis C, and noroviruses.

What technologies does Cocrystal employ?

Cocrystal uses advanced structure-based technologies and nucleoside chemistry to create first-in-class antiviral drugs, backed by Nobel Prize-winning expertise.

Who are some of Cocrystal Pharma's strategic investors?

Notable investors include Teva Pharmaceuticals, Opko Health, Dr. Raymond Schinazi, Brace Pharmaceutical, LLC, and The Frost Group.

How does Cocrystal's drug discovery approach differ from others?

Cocrystal's approach is market-focused and uses innovative nucleoside chemistry to efficiently deliver safe, effective, and convenient small molecule therapeutics.

What stage are Cocrystal's antiviral compounds in?

Cocrystal has identified promising preclinical stage antiviral compounds for various unmet medical needs.

What makes Cocrystal Pharma unique?

Cocrystal's unique blend of advanced technologies, Nobel Prize-winning expertise, and strong industry partnerships sets it apart in the biotechnology field.

Where can I find the latest news on Cocrystal Pharma?

Latest updates and relevant information about Cocrystal Pharma can be found on the StockTitan website, under the COCP stock section.

What is the main goal of Cocrystal Pharma?

The main goal of Cocrystal Pharma is to develop innovative antiviral therapeutics that effectively treat serious and chronic viral diseases.

Stock COCP logo
Cocrystal Pharma, Inc.

Nasdaq:COCP

COCP Rankings

#5255 Ranked by Market Cap
N/A Ranked by Dividends

COCP Stock Data

21.42M
6.93M
31.85%
6.94%
0.02%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOTHELL